To pay for the deal, Roche needed USD42 billion in cash. To meet that massive cash need, which was not fully available through bank USD32 billion in bonds at various maturities from 1 year to 30 years and in three different currencies (U.S. dollar, euro, and British pound). The sale would begin with the dollar-offering and followed up soon after with rounds of offering in the other currencies.